Meeting Presentations: Association for Research in Vision and Ophthalmology, Fort Lauderdale, May 2011; International Society of Ocular Oncology, Buenos Aires, November 2011.
Article first published online: 19 SEP 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 4, pages 688–693, April 2013
How to Cite
Berry, J. L., Jubran, R., Kim, J. W., Wong, K., Bababeygy, S. R., Almarzouki, H., Lee, T. C. and Murphree, A. L. (2013), Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr. Blood Cancer, 60: 688–693. doi: 10.1002/pbc.24303
Conflict of interest: Nothing to declare.
- Issue published online: 13 FEB 2013
- Article first published online: 19 SEP 2012
- Manuscript Accepted: 6 AUG 2012
- Manuscript Received: 29 MAY 2012
- Retinoblastoma International, Inc.
- The Institute for Families, Inc.
- Children's Hospital Los Angeles
Erratum: Jesse L. Berry, Rima Jubran, Jonathan W. Kim, Kenneth Wong, Simon R. Bababeygy, Hashem Almarzouki, Thomas C. Lee and A. Linn Murphree. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer 2013; 60: 688–693
Vol. 61, Issue 6, 1147, Article first published online: 16 APR 2014
- intensity-modulated radiation therapy;
- treatment outcomes
To evaluate outcomes of Group D eyes of bilateral retinoblastoma patients treated with primary chemoreduction and external beam radiation as salvage.
Retrospective chart review of patients diagnosed with bilateral retinoblastoma and designated Group D in at least one eye from January 1, 2000 to December 31, 2009. Overall, 62 Group D eyes of 49 patients were included; 13 had bilateral Group D disease. Primary chemoreduction with vincristine, etoposide, and carboplatin with local consolidation was administered, followed by external beam radiation in the form of intensity-modulated radiation therapy (IMRT) as salvage for recurrent tumor. Primary outcome measure was globe salvage.
Of 62 Group D eyes, 7 were enucleated primarily; 55 were treated with systemic chemoreduction, and local therapy. Chemoreduction cured 26 of 55 eyes (47%). Recurrences were found in 29 eyes; 5 underwent enucleation and 24 were treated with IMRT at a dose of 24 Gy (2 eyes) or 36 Gy (22 eyes). Of the 24 irradiated eyes, 19 (79%) were salvaged and 5 required enucleation. Final visual acuity ranged from 20/20 to light perception with 10 eyes having 20/80 or better visual acuity. Average follow-up was 54.2 months.
Kaplan–Meier estimates of eye survival of Group D eyes in bilateral patients at 12 months is 82% (95% confidence interval [CI] 70.1–89.7%); at 60 months eye survival is estimated to be 68% (95% confidence interval [CI] 55.4–82.8%). Systemic treatment for retinoblastoma demonstrated a high rate of globe preservation with acceptable complications and many eyes retaining functional vision. Pediatr Blood Cancer 2013; 60: 688–693. © 2012 Wiley Periodicals, Inc.